NCT04993222View on ClinicalTrials.gov

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

September 8, 2020

Study Completion Date

November 16, 2020

Conditions

Bioequivalence

Interventions

DRUG

Amphotericin B liposome for injection

IV infusion

DRUG

AmBisome®

IV infusion

Trial Locations (1)

430040

Wuhan Medical Treatment Center, Wuhan

All Listed Sponsors

lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

NCT04993222 - A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects | Biotech Hunter | Biotech Hunter